Zai Lab (ZLAB) stock is back in focus after the U.S. Food and Drug Administration granted Fast Track Designation to its DLL3-targeting antibody drug conjugate zoci for extrapulmonary neuroendocrine carcinomas.

The Fast Track news arrives after a mixed run for investors, with the share price up 8.54% year to date but the 1 year total shareholder return down 42.28% and the 5 year total shareholder return down 88.57%.

If you are weighing this kind of clinical catalyst against other healthcare opportunities, it can help to broaden the watchlist with 30 healthcare AI stocks.

With the stock trading at $18.81 and flagged by some metrics as trading at a discount to certain value estimates, the key question for you is whether this clinical momentum leaves upside on the table or if the market is already pricing in future growth.

Most Popular Narrative: 47% Undervalued

Against the last close at $18.81, the most followed valuation narrative points to a fair value of $35.34, setting up a wide gap investors will want to understand.

Multiple high-potential product launches and label expansions over the next 12-18 months (including VYVGART, bemarituzumab, KarXT, TIVDAK, Tumor Treating Fields), combined with a deep pipeline in oncology and immunology, are expected to significantly increase Zai Lab's addressable market and diversify revenue streams, supporting both top-line growth and future earnings.

Curious what kind of revenue trajectory and margin shift would need to play out for that valuation to hold up? The narrative leans on brisk top line expansion, a step change in profitability and a richer future earnings multiple that many investors usually associate with faster growing sectors.

Result: Fair Value of $35.34 (UNDERVALUED)

However, this hinges on China pricing and reimbursement decisions, and on Zai Lab managing reliance on partnered assets, both of which could dilute the bullish setup.

Next Steps

With mixed signals on valuation, risks and clinical progress, how comfortable are you with the balance of upside and downside here, and how quickly do you want to form your own view based on the full picture of 3 key rewards and 1 important warning sign?

Looking for more investment ideas?

If Zai Lab is on your radar, do not stop there. Broaden your opportunity set with other stocks that match different goals and risk profiles.

• Target potential mispricings by scanning a curated list of companies that look cheap on quality and valuation using the 51 high quality undervalued stocks.
• Prioritise resilience and sleep-at-night portfolios by building a shortlist from the 67 resilient stocks with low risk scores.
• Get ahead of the crowd by searching for tomorrow's potential standouts with the screener containing 21 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.